Base on the conclusions of that trial.
"Erlotinib with docetaxel met the 16-week PFS ≥ 30% endpoint, but overall survival was comparable to that seen with single-agent erlotinib. With the limitation of small numbers of patients, grade ≥ 2 rash (in BTC), and negative/low E-cadherin expression (HCC) were associated with higher PFS and OS."
Do you think it is still worthwhile to have join that clinical trial in stead of just taking the erlotinib 150mg daily even if the trial is available? Taxol and its derivatives like docetaxel are very tough to take.
But look at what I have just found an ORAL taxane -tesetaxel is on phase II trial and will report their findings in the upcoming ASCO2012 meeting. I will be there to listen to the findings.
See below :
"Genta Incorporated GNTA -12.50% announced today that its lead compound, tesetaxel, will be featured in multiple presentations of new clinical data at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held June 1-5, 2012, in Chicago, IL.
At the meeting, results from a confirmatory Phase 2 trial of tesetaxel, the leading oral taxane in clinical development, will be reported for overall response and progression-free survival (PFS) when used as 1st-line therapy for patients with hormone-refractory breast cancer. A second Phase 2 trial -- using tesetaxel as 2nd-line therapy for patients with advanced gastric cancer -- will report results on overall response and overall survival. A third presentation will report safety, pharmacokinetics, and the maximally tolerable dose (MTD) from a novel, weekly, dosing schedule. A final presentation will report data from a study of tesetaxel plus capecitabine (Xeloda(R); Hoffmann La Roche, Inc.), a drug combination that will be featured in Genta's late-stage clinical trials."
Please know that my personal opinion is not intended nor implied to be a substitute for professional medical advice. If provided, information are for educational purposes.Consult doctor is a MUST for changing of treatment plans.